Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3CNS 3Thoracic 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Glioblastoma 3Recurrence 1Glioma 1

Interventions

Temozolomide 165Magnetic Resonance Spectroscopy 130Radiotherapy 95Specimen Handling 80Radiosurgery 60Cyclophosphamide 55pembrolizumab 51Bevacizumab 51Nivolumab 48Radiation 47Carboplatin 34Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 23Topotecan 23Ipilimumab 23dinutuximab 21Cisplatin 21Blood Specimen Collection 21fludarabine 19Radiotherapy, Intensity-Modulated 19X-Rays 18Surgical Procedures, Operative 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
ADI PEG20 × CNS × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT07389278 2026-02-05

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

University of California, San Francisco

Phase 1/2 Not yet recruiting
97 enrolled
CNS

Glioblastoma, Glioma

NCT04587830 2025-08-26

GBM

Polaris Group

Phase 2 Active not recruiting
100 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡